California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

A slim-looking Elon Musk in a Santa suit with a revelation has set the social media on fire. Musk, the richest man in the world with a net worth of more than 470 billion Dollars, revealed that he ...

Elon Musk has admitted to taking a weight-loss drug in a Christmas Day post on X, formerly Twitter, as he shared a picture of ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating ...

Eli Lilly's obesity drug, Mounjaro, has been approved for public availability in Britain's NHS, expanding from its initial ...

Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...

Demand for Zepbound and Mounjaro has been so hot that Eli Lilly has struggled to make enough, leading the FDA to place it on ...

The result: The United Nations says that, at best, it will be able to raise enough money to help about 60% of the 307 million people it predicts will need humanitarian aid next year. That means at ...

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

Leveraging insights from OpenAI’s ChatGPT, Finbold has curated a $1,000 stock portfolio designed to capture growth ...

FDA has ordered specialty pharmacies and online companies to phase out knockoff versions of Eli Lilly's blockbuster drugs ...